HRDsig positivity has been reported in 82% of germline or somatic g/sBRCA1/BRCA2 or germline PALB2-mutated breast cancers and 16.5% of HRR wild-type cancers [52]. This evidence concerns the gene PALB2 and breast carcinoma.